{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:07:44Z","timestamp":1792670864248,"version":"4.5.0"},"reference-count":38,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"unspecified","delay-in-days":35,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vaccination remains the best strategy to reduce invasive meningococcal disease. This study evaluated an investigational tetanus toxoid-conjugate quadrivalent meningococcal vaccine (MenACYW-TT)<jats:italic>vs.<\/jats:italic>a licensed tetanus toxoid-conjugate quadrivalent meningococcal vaccine (MCV4-TT) (NCT02955797). Healthy toddlers aged 12\u201323 months were included if they were either meningococcal vaccine-na\u00efve or MenC conjugate (MCC) vaccine-primed (\u22651 dose of MCC prior to 12 months of age). Vaccine-na\u00efve participants were randomised 1:1 to either MenACYW-TT (<jats:italic>n<\/jats:italic>= 306) or MCV4-TT (<jats:italic>n<\/jats:italic>= 306). MCC-primed participants were randomised 2:1 to MenACYW-TT (<jats:italic>n<\/jats:italic>= 203) or MCV4-TT (<jats:italic>n<\/jats:italic>= 103). Antibody titres against each of the four meningococcal serogroups were measured by serum bactericidal antibody assay using the human complement. The co-primary objectives of this study were to demonstrate the non-inferiority of MenACYW-TT to MCV4-TT in terms of seroprotection (titres \u22651:8) at Day 30 in both vaccine-na\u00efve and all participants (vaccine-na\u00efve and MCC-primed groups pooled). The immune response for all four serogroups to MenACYW-TT was non-inferior to MCV4-TT in vaccine-na\u00efve participants (seroprotection: range 83.6\u201399.3% and 81.4\u201391.6%, respectively) and all participants (seroprotection: range 83.6\u201399.3% and 81.4\u201398.0%, respectively). The safety profiles of both vaccines were comparable. MenACYW-TT was well-tolerated and demonstrated non-inferior immunogenicity when administered to MCC vaccine-primed and vaccine-na\u00efve toddlers.<\/jats:p>","DOI":"10.1017\/s0950268821000261","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T13:12:41Z","timestamp":1612530761000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":24,"title":["Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)<i>vs<\/i>. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-na\u00efve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study"],"prefix":"10.1017","volume":"149","author":[{"given":"D.","family":"van der Vliet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Vesikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sandner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Martin\u00f3n-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Muzsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Forsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Adelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Diaz Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Simko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"B'Chir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Neveu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jordanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-7165","authenticated-orcid":false,"given":"M. S.","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"S0950268821000261_ref1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1528831"},{"key":"S0950268821000261_ref6","unstructured":"6. European Centre for Disease Prevention and Control, Disease data from ECDC Surveillance Atlas for meningococcal disease. Available at https:\/\/ecdc.europa.eu\/en\/meningococcal-disease\/surveillance-and-disease-data\/atlas."},{"key":"S0950268821000261_ref16","unstructured":"16. European Centre for Disease Prevention and Control, Vaccine schedules in all countries of the European Union. Available at https:\/\/vaccine-schedule.ecdc.europa.eu\/."},{"key":"S0950268821000261_ref9","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1051276"},{"key":"S0950268821000261_ref19","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7954-11-17"},{"key":"S0950268821000261_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(17)30157-3"},{"key":"S0950268821000261_ref21","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733867"},{"key":"S0950268821000261_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2016.03.041"},{"key":"S0950268821000261_ref13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.14745\/ccdr.v43i78a01","article-title":"Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009\u20132016","volume":"43","author":"Tsang","year":"2017","journal-title":"Canada Communicable Disease Report = Releve des maladies transmissibles au Canada"},{"key":"S0950268821000261_ref27","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318268dfe4"},{"key":"S0950268821000261_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.12.018"},{"key":"S0950268821000261_ref34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175721"},{"key":"S0950268821000261_ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.034"},{"key":"S0950268821000261_ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1554"},{"key":"S0950268821000261_ref26","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.4.2.156-167.1997"},{"key":"S0950268821000261_ref32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.14745\/ccdr.v45i06a04","article-title":"Increase in ST-11 serogroup W Neisseria meningitidis invasive meningococcal disease in Canada, 2016\u20132018","volume":"45","author":"Tsang","year":"2019","journal-title":"Canada Communicable Disease Report = Releve des maladies transmissibles au Canada"},{"key":"S0950268821000261_ref14","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1258308"},{"key":"S0950268821000261_ref25","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1593082"},{"key":"S0950268821000261_ref18","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268816000704"},{"key":"S0950268821000261_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.03.017"},{"key":"S0950268821000261_ref7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1532248"},{"key":"S0950268821000261_ref37","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1091908"},{"key":"S0950268821000261_ref5","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2012.0147"},{"key":"S0950268821000261_ref12","first-page":"E454","article-title":"Rise in invasive serogroup W meningococcal disease in Australia 2013\u20132015","volume":"40","author":"Martin","year":"2016","journal-title":"Communicable Diseases Intelligence Quarterly Report"},{"key":"S0950268821000261_ref8","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihw037"},{"key":"S0950268821000261_ref33","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001512"},{"key":"S0950268821000261_ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00321"},{"key":"S0950268821000261_ref15","first-page":"E121","article-title":"Meningococcal disease in childhood: epidemiology, clinical features and prevention","volume":"56","author":"Bosis","year":"2015","journal-title":"Journal of Preventive Medicine and Hygiene"},{"key":"S0950268821000261_ref31","first-page":"1800245","article-title":"Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017","volume":"24","author":"Krone","year":"2019","journal-title":"Euro Surveillance"},{"key":"S0950268821000261_ref11","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1434463"},{"key":"S0950268821000261_ref24","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733868"},{"key":"S0950268821000261_ref4","unstructured":"4. European Centre for Disease Prevention and Control, Invasive meningococcal disease: Annual Epidemiological Report for 2017. Available at https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER_for_2017-invasive-meningococcal-disease.pdf."},{"key":"S0950268821000261_ref23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733869"},{"key":"S0950268821000261_ref38","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.9.4946-4954.2002"},{"key":"S0950268821000261_ref28","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000750"},{"key":"S0950268821000261_ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.04.078"},{"key":"S0950268821000261_ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-0254-1"},{"key":"S0950268821000261_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16725-1"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268821000261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T05:59:29Z","timestamp":1619243969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268821000261\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":38,"alternative-id":["S0950268821000261"],"URL":"https:\/\/doi.org\/10.1017\/s0950268821000261","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2021. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e50"}}